Latest Advanced Therapies News

Page 3 of 3
Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.
Ada Torres
Ada Torres
31 Jan 2025
IDT Australia reports a near doubling of quarterly revenue to $5.3 million, driven by explosive growth in its Advanced Therapies segment, with first-half revenue expected to jump 82%.
Victor Sage
Victor Sage
28 Jan 2025

Browse the archive

Full archive